Drug Stock In Focus After FDA Resubmission

Short interest is high on OCUL

Emma Duncan

Managing Editor

Jun 29, 2018 at 10:10 AM

OCUL

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) are down 2.2% at $7.09 in early trading, after the company announced its New Drug Application (NDA) resubmission for its eye pain drug DEXTENZA, to the Food and Drug Administration (FDA). The company's President and CEO Antony Mattessich said it has made "substantial improvements" in the manufacturing of the pain drug.

Looking at the charts, Ocular Therapeutix stock has been trending higher since November, with pullbacks in recent months contained by the 50-day moving average. Overall, the drug concern has gained nearly 59% year-to-date.

Digging deeper, analyst sentiment has been extremely optimistic toward OCUL. As of yesterday, all six brokerage firms following the stock sport "strong buy" recommendations, while Ocular Therapeutix stock's average 12-month price target stands at $20.33 -- almost triple current levels.

Finally, short interest rose 2.7% during the most recent reporting period, and now represents nearly 20% of the stock's total available float. At OCUL's average price of daily trading, it would take over two weeks for shorts to cover their bearish bets.

Follow @Schaeffers

Are You Ready for AI's Potential Supercycle Phase?
Amazon's Jeff Bezos surprised investors when he revealed that one emerging technology is the key to Amazon's future success... This technology could be worth $80 trillion by 2030. Learn more and join Motley Fool's Stock Advisor for 50% off!

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.